NSEAnalysts/Institutional Investor Meet/Con. Call Updates19h ago · 18 Nov 2026, 12:38 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Alkem Laboratories Limited · ALKEM

✦ AI SummaryResults

Alkem Laboratories Limited has informed the Exchange about Q2 & H1FY2027 - Earnings Conference Call Transcript.

Analysis Scores

Earnings Impact8/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact9/10
Market Sentiment7/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Alkem Laboratories Limited has informed the Exchange about Q2 & H1FY2027 - Earnings Conference Call Transcript

Attachments (1)

📄

ALKEM_18112026123326_AlkemEarningsCallTranscript_signed.pdf

pdf

Download →
View document text
18th November, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Q2 & H1FY2027 - Earnings Conference Call Transcript Dear Sir(s) / Madam, We enclose herewith the transcript of “Q2 & H1FY2027 Earnings Conference Call” which was hosted by the Company on Thursday, 12th November, 2026. The said transcript shall also be made available on the website of the Company. Kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President - Legal, Company Secretary & Compliance Officer Encl.: a/a “Alkem Laboratories Limited Q2 FY27 Earnings Conference Call” November 12, 2026 MANAGEMENT: MR. SANDEEP SINGH – MANAGING DIRECTOR – ALKEM LABORATORIES LIMITED DR. AMRUT NAIK – CHIEF EXECUTIVE OFFICER – ALKEM LABORATORIES LIMITED MR. DISHANT HITESH DOSHI – DEPUTY CHIEF FINANCIAL OFFICER – ALKEM LABORATORIES LIMITED MR. SMEETT JAIN – HEAD OF INVESTOR RELATIONS – ALKEM LABORATORIES LIMITED MODERATOR: MR. TUSHAR MANUDHANE – MOTILAL OSWAL FINANCIAL SERVICES LIMITED Page 1 of 17 Alkem Laboratories Limited November 12, 2026 Moderator: Ladies and gentlemen, good morning and welcome to the Alkem Labs Q2 FY27 Earnings Conference Call hosted by Motilal Oswal Financial Services Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal for an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Tushar Manudhane. Thank you, and over to you, sir. Tushar Manudhane: Thanks, Shaurya. Good evening, everyone, and a warm welcome to the second quarter of FY 2027 earnings call of Alkem Laboratories. From the management side, we have Mr. Sandeep Singh, Managing Director, Dr. Amrut Naik, Chief Executive Officer, Mr. Dishant Hitesh Doshi, Deputy CFO, and Mr. Smeett Jain, Head of Investor Relations. Over to you, Smeett. Smeett Jain: Thank you, Tushar. Good evening, everyone. On behalf of Alkem Laboratories, I welcome you to our Quarter two FY 2027 earnings call. Earlier today, we announced our financial results along with the press release and investor presentation, all of which are filed with the stock exchanges and are also available on our website. We hope you had an opportunity to review them. Before we begin, I would like to remind everyone that this call is being recorded, and the audio recording and the transcript will be made available on the stock exchanges and our website shortly after the conclusion of the call. Please also note that today's discussion may include certain forward-looking statements, and these statements should be viewed in conjunction with the risks and uncertainties that are associated with our business and the environment in which we operate. With that, I now would like to hand over the call to our MD, Mr. Sandeep Singh, for his insights. Over to you, sir. Sandeep Singh: Thank you, Smeett. Good evening, everyone. Before I discuss the quarter's performance, I am pleased to welcome Dr. Amrut Naik, who has joined Alkem Labs as Chief Executive Officer. Dr. Naik brings extensive industry experience and will work closely with the leadership team to further strengthen execution and advance the group's strategic priorities. On behalf of the Alkem board and entire Alkem team, I welcome him and wish him great success in this new role. Before I go further, I would invite Amrut to introduce himself to the investors and analysts over here. Thank you. Amrut, over to you. Amrut Naik: Thank you, Sandeep. Good evening, all of you. Indeed a privilege and an honor to be here with you, and happy to have you on the call this afternoon. My name is Amrut Naik. I've joined Alkem as of yesterday as the CEO for the pharmaceutical business, and I come in with about 27 years of experience in the commercial area, leading businesses largely in overseas markets, including the developed and the developing world. Happy to speak further as we move forward. Thank you. Sandeep Singh: Thank you, Amrut. Page 2 of 17 Alkem Laboratories Limited November 12, 2026 Coming to quarter two, we saw a healthy momentum across our India and international business. Our India formulations business performed broadly in line with the market, supported by continued strength in the chronic portfolio. The non-U.S. markets delivered steady underlying performance, led by LATAM, while reported growth also benefited from the integration of Occlutech. In the U.S., volume growth provided support despite the prevailing pricing environment. We also made progress across our newer growth platforms. During the quarter, we integrated Occlutech into our MedTech business, with its financial performance consolidated into our results from this quarter. In biotech, improving execution of operating performance at Enzene remains a key priority. As we move into the second half, our focus remains on sustaining growth in the core business and strengthening execution across our operations, addressing regulatory priorities in Daman, and developing our MedTech and biotech platforms in a disciplined manner. I will briefly walk you through the key developments and outlook, after which we'll be happy to take your questions and engage in discussions. Our revenue from operations was INR4,520 crores, year-on-year growth of 13.8%. Biotech sales was INR 70 crores with year-on-year degrowth of 35%, but that's due to the lumpy business nature of the CDMO. MedTech sales were INR 133 crores. That includes Occlutech. EBITDA was INR1,025 crores, resulted in a EBITDA margin of 22.5%, a growth of 11.3% year- on-year. R&D expenses were 4.3% of our revenues. Profit before tax grew 7.7% year-on-year. Net profit saw a degrowth of 11.7%, and net cash stood at INR4,900 crores plus. According to IQVIA, we saw the company register a growth of 13.8% year-on-year, at par with the Indian pharmaceutical industry, which grew at 13.8% as well. Acute segment reported a growth of 12.1% at par with the IPM growth of 12.3%. Chronic segment reported a growth of 22.4% versus the industry, which grew by 16%, 640 basis points outperformance. We have outperformed IPM in eight key focus therapies. In multivitamins by ~1.2x, anti-diabetic again ~1.5x, cardiac by 1.1x. Urology, again on a low base, we are 1.1x, Respiratory by 1.6x, Neuro CNS by 1.1x & Derma by 1.6x. On the regulatory front, remediation of our Daman facility is progressing, and we remain engaged with the U.S. FDA to address the observation related to its OAI status. Separately, the U.S. FDA inspection of our Mandva API facility concluded with no 483s. We are also committed to maintaining the highest standards of quality and compliance across all our sites. Thank you. With this, we open the floor for Q&A. Moderator: Thank you very much. We will now begin with the question-and-answer session. The first question is from the line of Saion Mukherjee from Nomura. Please go ahead. Page 3 of 17 Alkem Laboratories Limited November 12, 2026 Saion Mukherjee: On the India business, if you can highlight the dynamics that is leading to the slowdown in the trade generics segment, and also on the prescription business, how you see growth shaping up for the rest of the year and also for FY28? Sandeep Singh: On trade generics, I think it is a question of just intensity going up of the market. I mean, I have said this before, like few years back, there were much fewer players. Now you have all the biggies jumping on the bandwagon as well. That is one. Number two, we have tightened our own credit policies as well. So these kind of things have led to a growth, I mean, to a situation where our growth is no longer the histor [Showing first 8,000 characters — download PDF for full document]